AbbVie Inc. shares fell following the company's decision to lower its 2026 financial guidance. The revision reflects the impact of its recent acquisition of Apogee Therapeutics.
AbbVie Shares Decline After 2026 Guidance Cut on Apogee Acquisition
|1 min read
AbbViePharmaceuticalsEarnings GuidanceM&ABiotech
